1. Scrip
  2. >>Business

Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients

Dexamethasone Remains Only Proven Therapy In Severe Disease

 
• By Andrew McConaghie

Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
The trial aimed to help hospitalized patients not yet on mechanical ventilation but failed to show an impact on mortality rates. • Source: Archive

Novartis’s anti-inflammatory drug canakinumab has failed to cut deaths in a trial involving critically ill COVID-19 patients with pneumonia and cytokine release syndrome (CRS).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip